Vol. 15 nº 4 - Oct/Nov/Dec de 2021
Original Article Páginas: 421 a 427

A review of Cochrane reviews on pharmacological treatment for attention deficit hyperactivity disorder

Authors Giovanna Marcílio Santos1; Elaine Marcílio Santos2; Gustavo Duarte Mendes2; ara Dadalti Fragoso2; Mariani Rafaela Souza2; Ana Luiza Cabrera Martimbianco1


keywords: attention deficit hyperactivity disorder, systematic review, desipramine, amphetamine, methylphenidate.

Attention deficit hyperactivity disorder (ADHD) is one of the most frequent childhood psychiatric problems.
OBJECTIVE: The objective of this study was to identify, synthesize the results, and critically evaluate all Cochrane systematic reviews (SRs) on the pharmacological interventions for children and adolescents (up to age 18) diagnosed with ADHD.
METHODS: The search was performed in the Cochrane Database of Systematic Reviews (via Wiley) in July 2020.
RESULTS: The search strategy resulted in four SRs of high methodological quality, analyzing 51 randomized clinical trials (9,013 participants). Compared to placebo, treatment with tricyclic antidepressants (TCAs) (desipramine), amphetamine, and methylphenidate showed improvement in symptoms such as difficulty concentrating, impulsivity, and hyperactivity in the short term (up to 6 months). There was an increase in the occurrence of adverse events, such as reduced appetite, difficulty sleeping, and abdominal pain. Insufficient evidence was found to support the effects of supplementation with polyunsaturated fatty acids.
CONCLUSIONS: The use of TCAs, amphetamine, and methylphenidate in children and adolescents with ADHD seems to present positive effects and higher rates of minor adverse events when compared to placebo.


Home Contact